康龍化成(03759.HK)擬發行約6億美元零息可轉換債券 轉換價溢價逾29%
格隆匯6月9日丨康龍化成(03759.HK)公佈，於2021年6月8日，公司及聯席牽頭經辦人訂立認購協議，公司已同意發行，而聯席牽頭經辦人個別而非共同同意認購併支付，或促使認購人認購併支付本金額為3億美元的第一批於2026年到期的零息可轉換債券及本金額為人民幣19.16億元的第二批於2026年到期的美元結算零息可轉換債券。
第一批債券及第二批債券可於條款及條件所載情況下分別按初步第一批債券轉換價每股H股250.75港元及第二批債券轉換價每股H股229.50港元轉換為H股。初步第一批債券轉換價每股H股250.75港元，較6月8日收市價每股H股177.50港元溢價41.27%。初步第二批債券轉換價每股H股229.50港元，較6月8日收市價每股H股177.50港元溢價29.30%。
假設按初步第一批債券轉換價每股H股250.75港元悉數轉換第一批債券，則第一批債券將轉換為約928.3萬股H股，相當於已發行總H股股本約6.93%，以及公司悉數轉換第一批債券後但轉換第二批債券前的經擴大已發行總H股股本約6.48%。
假設按初步第二批債券轉換價每股H股229.50港元悉數轉換第二批債券，則第二批債券將轉換為約1013.77萬股H股，相當於已發行總H股股本約7.56%，以及公司悉數轉換第二批債券後但轉換第一批債券前的經擴大已發行總H股股本約7.03%。
第一批債券及第二批債券認購事項估計所得款項淨額將約為5.875億美元。公司所得款項淨額的擬定用途為：(i)擴展小分子藥物的藥物工藝開發及生產設施（即CMC服務）的產能及能力；(ii)擴展大分子藥物研發和生產服務平台；(iii)擴展藥物安全性評價實驗室服務的能力；(iv)擴展英國實驗室及生產設施之產能及能力；及(v)補充流動資金及其他一般企業用途。
董事會認為，發行債券能為獲取可長遠及更好地支持公司業務擴張的可即時動用資金池締造良機。董事會現時擬將資金用作上述用途，並認為此舉將有利於集團的整體發展及擴張。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
